LTX-109 as Treatment for Hidradenitis Suppurativa

Summary

An Open label Phase II//proof of concept-study to demonstrate if percutaneous application of LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify clinical response to intervention, as well to identify if covariates such as age, disease duration, smoking state and BMI influence patient reported measures.

Timeline

Start

2021-03-05

Primary completion

2021-07-01

Completion

2021-07-01

Drugs

Indications